Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.

The synthesis, in vitro properties, and in vivo pharmacokinetics for a series of sulfoximine-substituted trifluoromethylpyrimidines as inhibitors of proline-rich tyrosine kinase, a target for the possible treatment of osteoporosis, are described. These compounds were prepared as surrogates of the corresponding sulfone compound 1. Sulfone 1 was an attractive PYK2 lead compound; however, subsequent studies determined this compound possessed high dofetilide binding, which is an early indicator of cardiovascular safety. Surprisingly, the corresponding sulfoximine analogs displayed significantly lower dofetilide binding, which, for N-methylsulfoximine (S)-14a, translated to lower activity in a patch clamp hERG K(+) ion channel screen. In addition, compound (S)-14a shows good oral exposure in a rat pharmacokinetic model.

[1]  L. Reiner,et al.  The Reaction of Hydrazoic Acid with Thioether-sulfoxides: Synthesis of Sulfoximines , 1951 .

[2]  Leonard Buckbinder,et al.  Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design , 2009, Journal of Biological Chemistry.

[3]  Y. Sham,et al.  Design and synthesis of sulfoximine based inhibitors for HIV-1 protease. , 2008, Bioorganic & medicinal chemistry letters.

[4]  V. Paralkar,et al.  Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis , 2007, Proceedings of the National Academy of Sciences.

[5]  C. Bolm,et al.  Sulfoximines in pseudopeptides , 1997 .

[6]  B. Raguse,et al.  The N-alkylation of sulfoximines , 1986 .

[7]  Gary A Gintant,et al.  The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. , 2004, Journal of pharmacological and toxicological methods.

[8]  T. Kensler,et al.  Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone 1α,25-Dihydroxyvitamin D3 , 2004 .

[9]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[10]  T. Baillie,et al.  Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. , 2004, Chemical research in toxicology.

[11]  A. Dubin,et al.  Identifying Modulators of hERG Channel Activity Using the PatchXpress® Planar Patch Clamp , 2005, Journal of biomolecular screening.

[12]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[13]  Christopher Autry,et al.  Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor* , 2007, Journal of Biological Chemistry.

[14]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[15]  J. Boyd,et al.  The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. , 2004, Journal of pharmaceutical and biomedical analysis.

[16]  J. Sikorski.  Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. , 2006, Journal of medicinal chemistry.

[17]  Z. Rankovic,et al.  Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.

[18]  M. Reggelin,et al.  Sulfoximines: Structures, Properties and Synthetic Applications , 2000 .

[19]  Leonard Buckbinder,et al.  Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation. , 2008, Bioorganic & medicinal chemistry letters.

[20]  J. Uetrecht,et al.  Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. , 2002, Current drug metabolism.

[21]  Dong Won Kim,et al.  A Mild and Highly Efficient Oxidation of Sulfides to Sulfoxides with Periodic Acid Catalyzed by FeCl3 , 2002 .

[22]  C. January,et al.  [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. , 2001, European journal of pharmacology.

[23]  Carl R. Johnson,et al.  Chemistry of sulfoxides and related compounds. XXXIII. Stereochemistry of substitution at tetracoordinate hexavalent sulfur. Nucleophilic reactions at sulfur in sulfonimidoyl compounds , 1971 .